Una nueva investigación vuelve a destacar el interferón beta inhalado como tratamiento para el Covid-19 20minutos.es - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from 20minutos.es Daily Mail and Mail on Sunday newspapers.
A UNIVERSITY is set to work on a £10m research project exploring new ways to diagnose lung cancer. The Universities of both Southampton and Leeds have come together with healthcare, diagnostics and informatics companies to test the best way of detecting cancers at a stage when they can still be cured, linking to the NHS England Targeted Lung Health Checks programme. The project, called iDx-LUNG, is part of the Government’s Early Diagnosis Mission to diagnose three-quarters of cancers at an early stage by 2028. Work is able to proceed thanks to approximately £3.5m worth of funding from UK Research and Innovation’s Industrial Strategy Challenge Fund (ISCF), part of a total investment of £10 million in the programme overall.
A shadow over the promising inhaled interferon beta COVID-19 therapy has been cleared with the discovery that although it appears to increase levels of.
With every jab in the arm, Britain moves a step closer to defeating COVID-19. That was the message from the prime minister as he imposed another lockdown. It’s a hopeful line – but will vaccines alone truly be sufficient to put an end to this pandemic? I think not.
Major Research At Southampton To Detect Lung Cancer Earlier
Southampton University and Leeds University have collaborated with major companies to find a way of detecting lung cancers at an early enough stage to cure them.
Companies such as Johnson & Johnson, Roche, Oncimmune, Inivata, BC Platforms, and others are working with the universities after £3.5m worth of funding was made available from the UK Research and Innovation’s Industrial Strategy Challenge Fund, which will help the government’s Early Diagnosis Mission.
The Early Diagnosis Mission is an ambition to diagnose three-quarters of cancers at an early stage by 2028.
Professor Peter Johnson, Professor of Medical Oncology at the University of Southampton, who is leading the project, told the University: